Page last updated: 2024-10-24

caffeine and ADDH

caffeine has been researched along with ADDH in 45 studies

Research Excerpts

ExcerptRelevanceReference
"This aim of this study was to conduct a systematic literature review on the association between maternal caffeine intake during pregnancy and attention deficit hyperactivity disorder (ADHD) in childhood."8.91[Caffeine consumption during pregnancy and attention deficit hyperactivity disorder (ADHD): a systematic literature review]. ( Anselmi, L; Santos, IS; Schmidt, V; Silva, Bdel P, 2015)
"Studies evaluating caffeine intake during pregnancy and long-term outcomes, such as the child's neurobehaviour, are still scarce and their results are inconsistent."7.83Caffeine consumption during pregnancy and ADHD at the age of 11 years: a birth cohort study. ( Anselmi, L; Del-Ponte, B; Matijasevich, A; Munhoz, TN; Santos, IS; Tovo-Rodrigues, L, 2016)
"Human studies that have investigated the association between caffeine intake during pregnancy and offspring's behavioral outcomes are scant and inconclusive."7.78Caffeine intake during pregnancy and risk of problem behavior in 5- to 6-year-old children. ( Hofland, L; Koot, HM; Loomans, EM; Van den Bergh, BR; van der Stelt, O; van der Wal, MF; Vrijkotte, TG, 2012)
"Caffeine is a central nervous system stimulant and acts in the brain through adenosine receptors, influencing attention, alertness, and anxiety."5.72Caffeine-related genes influence anxiety disorders in children and adults with ADHD. ( Bandeira, CE; Bau, CHD; Contini, V; da Silva, BS; Dresch, F; Fraporti, TT; Genro, JP; Grevet, EH; Hutz, MH; Martins-Silva, T; Rohde, LA; Rovaris, DL; Tovo-Rodrigues, L, 2022)
" Findings with alcohol and caffeine exposures and conduct disorder and oppositional-defiant disorder need more research, using more genetically sensitive designs."5.22Prenatal smoking, alcohol and caffeine exposure and offspring externalizing disorders: a systematic review and meta-analysis. ( Haan, E; Munafò, MR; Sallis, HM; Schellhas, L; Taylor, G; Westmoreland, KE; Zuccolo, L, 2022)
"This aim of this study was to conduct a systematic literature review on the association between maternal caffeine intake during pregnancy and attention deficit hyperactivity disorder (ADHD) in childhood."4.91[Caffeine consumption during pregnancy and attention deficit hyperactivity disorder (ADHD): a systematic literature review]. ( Anselmi, L; Santos, IS; Schmidt, V; Silva, Bdel P, 2015)
"The purpose of this review was to examine the literature assessing the relationship between prenatal exposure to nicotine, alcohol, caffeine, and psychosocial stress during pregnancy to the risk of developing behavioral problems related to attention deficit hyperactivity disorder (ADHD) in childhood."4.82Maternal lifestyle factors in pregnancy risk of attention deficit hyperactivity disorder and associated behaviors: review of the current evidence. ( Dalsgaard, S; Henriksen, TB; Jarvelin, MR; Kotimaa, A; Linnet, KM; Moilanen, I; Obel, C; Olsen, J; Rodriguez, A; Thomsen, PH; Wisborg, K, 2003)
"Studies evaluating caffeine intake during pregnancy and long-term outcomes, such as the child's neurobehaviour, are still scarce and their results are inconsistent."3.83Caffeine consumption during pregnancy and ADHD at the age of 11 years: a birth cohort study. ( Anselmi, L; Del-Ponte, B; Matijasevich, A; Munhoz, TN; Santos, IS; Tovo-Rodrigues, L, 2016)
"Human studies that have investigated the association between caffeine intake during pregnancy and offspring's behavioral outcomes are scant and inconclusive."3.78Caffeine intake during pregnancy and risk of problem behavior in 5- to 6-year-old children. ( Hofland, L; Koot, HM; Loomans, EM; Van den Bergh, BR; van der Stelt, O; van der Wal, MF; Vrijkotte, TG, 2012)
"Caffeine treatment increases attention and improves learning, memory, and olfactory discrimination without altering blood pressure and body weight."2.82Effects of Caffeine Consumption on Attention Deficit Hyperactivity Disorder (ADHD) Treatment: A Systematic Review of Animal Studies. ( López Palomé, J; Martin de la Torre, O; Redolar-Ripoll, D; Vázquez, JC, 2022)
"Caffeine produced an increase in SCL, and this increase did not differ between the groups."2.77Caffeine effects on resting-state electrodermal levels in AD/HD suggest an anomalous arousal mechanism. ( Barry, RJ; Clarke, AR; Dupuy, FE; MacDonald, B; McCarthy, R; Selikowitz, M, 2012)
"Methylphenidate was added to both dosages, as well as administered alone."2.65Responses to methylphenidate and varied doses of caffeine in children with attention deficit disorder. ( Garfinkel, BD; Sloman, L; Webster, CD, 1981)
"Eight children with minimal brain dysfunction were studied for their individual responses to two stimulant medications--methylphenidate hydrochloride and caffeine citrate."2.64Individual responses to methylphenidate and caffeine in children with minimal brain dysfunction. ( Garfinkel, BD; Sloman, L; Webster, CD, 1975)
"Caffeine is a central nervous system stimulant and acts in the brain through adenosine receptors, influencing attention, alertness, and anxiety."1.72Caffeine-related genes influence anxiety disorders in children and adults with ADHD. ( Bandeira, CE; Bau, CHD; Contini, V; da Silva, BS; Dresch, F; Fraporti, TT; Genro, JP; Grevet, EH; Hutz, MH; Martins-Silva, T; Rohde, LA; Rovaris, DL; Tovo-Rodrigues, L, 2022)
"Caffeine use was not associated with actigraphy-assessed sleep."1.56Caffeine Use and Associations With Sleep in Adolescents With and Without ADHD. ( Becker, SP; Breaux, R; Cusick, CN; Green, CD; Langberg, JM, 2020)
"Nowadays the pharmacological treatment of the attention deficit hyperactivity disorder (ADHD) is based on amphetamine derivatives (i."1.37Caffeine improves attention deficit in neonatal 6-OHDA lesioned rats, an animal model of attention deficit hyperactivity disorder (ADHD). ( Ahern, S; Caballero, M; Carbonell, L; Ciruela, F; Cuffí, ML; Fernández-Dueñas, V; Núñez, F; Sánchez, S, 2011)
"Thirty youth with major depressive disorder (MDD) and 23 control youth reported on caffeine use, sleep, and affect in their natural environment using ecological momentary assessment at baseline and over 8 weeks, while MDD youth received treatment."1.35Caffeine consumption, sleep, and affect in the natural environments of depressed youth and healthy controls. ( Axelson, DA; Birmaher, B; Dahl, RE; Forbes, EE; Ryan, ND; Semel, M; Silk, JS; Whalen, DJ, 2008)
"Caffeine has been found to alter the behavior of ADD children in a manner resembling more widely prescribed stimulant medications."1.27Will population decreases in caffeine consumption unveil attention deficit disorders in adults? ( Dalby, JT, 1985)

Research

Studies (45)

TimeframeStudies, this research(%)All Research%
pre-19909 (20.00)18.7374
1990's1 (2.22)18.2507
2000's10 (22.22)29.6817
2010's14 (31.11)24.3611
2020's11 (24.44)2.80

Authors

AuthorsStudies
Haan, E2
Sallis, HM2
Zuccolo, L2
Labrecque, J1
Ystrom, E1
Reichborn-Kjennerud, T1
Andreassen, O1
Havdahl, A1
Munafò, MR2
Fraporti, TT1
Bandeira, CE1
Tovo-Rodrigues, L2
Martins-Silva, T1
Hutz, MH1
Rohde, LA1
Bau, CHD1
Grevet, EH1
da Silva, BS1
Rovaris, DL1
Dresch, F1
Contini, V1
Genro, JP1
Musafia, B1
Rosenberg, G1
Vázquez, JC1
Martin de la Torre, O1
López Palomé, J1
Redolar-Ripoll, D1
Westmoreland, KE1
Schellhas, L1
Taylor, G1
Dash, GF3
Carter, E3
Karalunas, SL3
Hudson, KA3
Fair, D3
Feldstein Ewing, SW3
Atila, O1
Deniz, E1
Ari, A1
Sengur, A1
Chakraborty, S1
Barua, PD1
Acharya, UR1
Alves, CB1
Almeida, AS2
Marques, DM2
Faé, AHL1
Machado, ACL1
Oliveira, DL1
Portela, LVC1
Porciúncula, LO3
Cusick, CN1
Langberg, JM1
Breaux, R1
Green, CD1
Becker, SP1
França, AP1
Schamne, MG1
de Souza, BS1
da Luz Scheffer, D1
Bernardelli, AK1
Corrêa, T1
de Souza Izídio, G1
Latini, A1
da Silva-Santos, JE1
Canas, PM1
Cunha, RA3
Prediger, RD4
Kahathuduwa, CN1
Wakefield, S1
West, BD1
Blume, J1
Dassanayake, TL1
Weerasinghe, VS1
Mastergeorge, A1
Nunes, F1
Pochmann, D1
Leffa, DT1
Ferreira, SG1
Machado, NJ2
Souza, CM1
Rosa, FD1
de Carvalho, C1
Kincheski, GC1
Takahashi, RN5
Souza, DO1
Pandolfo, P4
Ioannidis, K1
Chamberlain, SR1
Müller, U1
Silva, Bdel P1
Anselmi, L2
Schmidt, V1
Santos, IS2
Chinthapalli, K1
Del-Ponte, B1
Munhoz, TN1
Matijasevich, A1
Linnet, KM2
Wisborg, K2
Secher, NJ1
Thomsen, PH2
Obel, C2
Dalsgaard, S2
Henriksen, TB2
Pires, VA2
Pamplona, FA3
Fernandes, D2
Bekkhus, M1
Skjøthaug, T1
Nordhagen, R1
Borge, AI1
Liu, K1
Liang, X1
Kuang, W1
Caballero, M1
Núñez, F1
Ahern, S1
Cuffí, ML1
Carbonell, L1
Sánchez, S1
Fernández-Dueñas, V1
Ciruela, F1
Barry, RJ1
Clarke, AR1
McCarthy, R1
Selikowitz, M1
MacDonald, B1
Dupuy, FE1
Köfalvi, A1
Loomans, EM1
Hofland, L1
van der Stelt, O1
van der Wal, MF1
Koot, HM1
Van den Bergh, BR1
Vrijkotte, TG1
Ouchi, H1
Ono, K1
Murakami, Y1
Matsumoto, K1
Rodriguez, A1
Kotimaa, A1
Moilanen, I1
Olsen, J1
Jarvelin, MR1
Jafri, SH1
Cook, JW1
Reed, RR1
Beebe, DK1
Pomerleau, CS1
Pomerleau, OF1
Snedecor, SM1
Gaulrapp, S1
Kardia, SL1
Pereira, RR1
van de Wetering, BJ1
Bramstedt, KA1
Wammanda, RD1
Whalen, DJ1
Silk, JS1
Semel, M1
Forbes, EE1
Ryan, ND1
Axelson, DA1
Birmaher, B1
Dahl, RE1
Garfinkel, BD3
Webster, CD3
Sloman, L3
Krummel, DA1
Seligson, FH1
Guthrie, HA1
Stephenson, PE1
Arnold, LE2
Christopher, J1
Huestis, R1
Smeltzer, DJ2
Huestis, RD1
Gross, MD1
Rapoport, JL1
Dalby, JT1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Pharmacological Treatment of Rett Syndrome by Stimulation of Synaptic Maturation With Recombinant Human IGF-1(Mecasermin [rDNA] Injection)[NCT01777542]Phase 230 participants (Actual)Interventional2013-01-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Aberrant Behavior Checklist - Community Edition (ABC-C)

"The ABC-C is a global behavior checklist implemented for the measurement of drug and other treatment effects in populations with intellectual disability. Behavior based on 58 items that describe various behavioral problems.~Each item is rated on the parents perceived severity of the behavior. The answer options for each item are:~0 = Not a problem~= Problem but slight in degree~= Moderately serious problem~= Severe in degree~The measure is broken down into the following subscales with individual ranges as follows:~Subscale I (Irritability): 15 items, score range = 0-45 Subscale II (Lethargy): 16 items, score range = 0-48 Subscale III (Stereotypy): 7 items, score range = 0-21 Subscale IV (Hyperactivity): 16 items, score range = 0-48 Subscale V (Inappropriate Speech) was not included in the breakdown because it was not applicable (no participants in the study had verbal language)." (NCT01777542)
Timeframe: Every 5 weeks during each of the two 20-week treatment periods, and once 4 weeks after final treatment ends

,
Interventionunits on a scale (Median)
Visit 1 - First Intervention: Subscale IVisit 3 - First Intervention: Subscale IVisit 5 - First Intervention: Subscale IVisit 6 - Second Intervention: Subscale IVisit 8 - Second Intervention: Subscale IVisit 10 - Second Intervention: Subscale IFollow-up: Subscale I (Irritability)Visit 1 - First Intervention: Subscale IIVisit 3 - First Intervention: Subscale IIVisit 5 - First Intervention: Subscale IIVisit 6 - Second Intervention: Subscale IIVisit 8 - Second Intervention: Subscale IIVisit 10 - Second Intervention: Subscale IIFollow-up: Subscale II (Lethargy)Visit 1 - First Intervention: Subscale IIIVisit 3 - First Intervention: Subscale IIIVisit 5 - First Intervention: Subscale IIIVisit 6 - Second Intervention: Subscale IIIVisit 8 - Second Intervention: Subscale IIIVisit 10 - Second Intervention: Subscale IIIFollow-up: Subscale III (Stereotypy)Visit 1 - First Intervention: Subscale IVVisit 3 - First Intervention: Subscale IVVisit 5 - First Intervention: Subscale IVVisit 6 - Second Intervention: Subscale IVVisit 8 - Second Intervention: Subscale IVVisit 10 - Second Intervention: Subscale IVFollow-up: Subscale IV (Hyperactivity)
Placebo First, Then rhIGF-19.009.007.007.004.005.003.0013.0011.009.0011.008.006.006.0013.0010.0011.0011.0010.008.008.0013.0012.0011.0011.007.0010.009.00
rhIGF-1 First, Then Placebo6.004.002.004.003.005.002.008.007.006.005.005.004.005.0012.0010.009.0011.009.009.009.008.008.006.007.004.005.005.00

Anxiety, Depression, and Mood Scale (ADAMS)

"Remaining subscales of the ADAMS that are not primary outcome measures include: Manic/hyperactive, Depressed mood, General anxiety, Obsessive/compulsive behavior.~The range for each subscale is as follows:~Manic/Hyperactive Behavior: 0-15 Depressed Mood: 0-21 General Anxiety: 0-21 Obsessive/Compulsive Behavior: 0-9~The higher the score for each subscale, the more problematic the behavior." (NCT01777542)
Timeframe: Every 5 weeks during each of the two 20-week treatment periods, and once 4 weeks after final treatment ends

,
Interventionunits on a scale (Median)
Visit 1- First Intervention: Manic/HyperactiveVisit 2- First Intervention: Manic/HyperactiveVisit 3- First Intervention: Manic/HyperactiveVisit 4- First Intervention: Manic/HyperactiveVisit 5- First Intervention: Manic/HyperactiveVisit 6- Second Intervention: Manic/HyperactiveVisit 7- Second Intervention: Manic/HyperactiveVisit 8- Second Intervention: Manic/HyperactiveVisit 9- Second Intervention: Manic/HyperactiveVisit 10- First Intervention: Manic/HyperactiveFollow-up: Manic/Hyperactive SubscaleVisit 1- First Intervention: Depressed MoodVisit 2- First Intervention: Depressed MoodVisit 3- First Intervention: Depressed MoodVisit 4- First Intervention: Depressed MoodVisit 5- First Intervention: Depressed MoodVisit 6- Second Intervention: Depressed MoodVisit 7- Second Intervention: Depressed MoodVisit 8- Second Intervention: Depressed MoodVisit 9- Second Intervention: Depressed MoodVisit 10- Second Intervention: Depressed MoodFollow-up: Depressed Mood SubscaleVisit 1- First Intervention: General AnxietyVisit 2- First Intervention: General AnxietyVisit 3- First Intervention: General AnxietyVisit 4- First Intervention: General AnxietyVisit 5- First Intervention: General AnxietyVisit 6- Second Intervention: General AnxietyVisit 7- Second Intervention: General AnxietyVisit 8- Second Intervention: General AnxietyVisit 9- Second Intervention: General AnxietyVisit 10- Second Intervention: General AnxietyFollow-up: General Anxiety SubscaleVisit 1- First Intervention: Obsessive CompulsiveVisit 2- First Intervention: Obsessive CompulsiveVisit 3- First Intervention: Obsessive CompulsiveVisit 4- First Intervention: Obsessive CompulsiveVisit 5- First Intervention: Obsessive CompulsiveVisit 6- Second Intervention: Obsessive CompulsiveVisit 7- Second Intervention: Obsessive CompulsiveVisit 8- Second Intervention: Obsessive CompulsiveVisit 9- Second Intervention: Obsessive CompulsiveVisit 10- First Intervention: Obsessive CompulsiveFollow-up: Obsessive Compulsive Behavior Subscale
Placebo First, Then rhIGF-18.007.007.007.007.008.006.506.006.005.005.002.004.003.002.002.002.003.002.003.002.002.008.006.006.005.005.006.006.006.004.004.005.504.004.004.003.003.003.003.003.003.002.003.50
rhIGF-1 First, Then Placebo7.007.006.005.004.006.005.005.004.004.505.004.005.003.003.004.004.003.003.002.003.003.506.007.006.005.005.007.005.004.003.004.004.003.004.004.003.003.003.003.003.002.002.503.00

Anxiety, Depression, and Mood Scale (ADAMS) - Social Avoidance Subscale

"The ADAMS is completed by the parent/caregiver/LAR and consists of 29 items which are scored on a 4-point rating scale that combines frequency and severity ratings. The instructions ask the rater to describe the individual's behavior over the last six months on the following scale: 0 if the behavior has not occurred, 1 if the behavior occurs occasionally or is a mild problem, 2 if the behavior occurs quite often or is moderate problem, or 3 if the behavior occurs a lot or is a severe problem.~The Social Avoidance subscale of the ADAMS will be used as a primary outcome measure for this trial. The range for this subscale is 0-21. The higher the subscale score, the more problematic the behavior." (NCT01777542)
Timeframe: Every 5 weeks during each of the two 20-week treatment periods, and once 4 weeks after final treatment ends

,
Interventionunits on a scale (Median)
Visit 1 - First InterventionVisit 2 - First InterventionVisit 3 - First InterventionVisit 4 - First InterventionVisit 5 - First InterventionVisit 6 - Second InterventionVisit 7 - Second InterventionVisit 8 - Second InterventionVisit 9 - Second InterventionVisit 10 - Second InterventionFollow-up
Placebo First, Then rhIGF-16.005.005.006.005.004.004.004.003.003.504.00
rhIGF-1 First, Then Placebo4.005.004.004.003.004.004.004.003.003.503.00

Clinical Global Impression - Improvement (CGI-I)

"Each time the patient was seen after the study intervention was initiated, the clinician compared the patient's overall clinical condition to the CGI-S score obtained at the baseline (visit 1) visit. Based on information collected, the clinician determined if any improvement occurred on the following 7-point scale: 1=Very much improved since the initiation of treatment; 2=Much improved; 3=Minimally improved; 4=No change from baseline (the initiation of treatment); 5=Minimally worse; 6=Much worse; 7=Very much worse since the initiation of treatment.~The possible range for reported scores is 1-7." (NCT01777542)
Timeframe: Every 10 weeks during each of the two 20-week treatment periods

,
Interventionunits on a scale (Median)
Visit 3 - First InterventionVisit 5 - First InterventionVisit 6 - Second InterventionVisit 8 - Second InterventionVisit 10 - Second Intervention
Placebo First, Then rhIGF-14.004.004.004.004.00
rhIGF-1 First, Then Placebo4.004.004.004.004.00

Clinical Global Impression - Severity (CGI-S)

"This scale is used to judge the severity of the subject's disease prior to entry into the study. The clinician will rate the severity of behavioral symptoms at baseline on a 7-point scale from not impaired to the most impaired.~The scores that correspond to each possible grouping are as follows: 1=Normal, not at all impaired; 2=Borderline impaired; 3=Mildly impaired; 4=Moderately impaired; 5=Markedly impaired; 6=Severely impaired; 7=The most impaired.~The possible range for reported scores is 1-7." (NCT01777542)
Timeframe: Every 10 weeks during each of the two 20-week treatment periods

,
Interventionunits on a scale (Median)
Visit 1 - First InterventionVisit 3 - First InterventionVisit 5 - First InterventionVisit 6 - Second InterventionVisit 8 - Second InterventionVisit 10 - Second Intervention
Placebo First, Then rhIGF-14.004.004.004.004.004.00
rhIGF-1 First, Then Placebo4.004.004.004.004.004.50

Communication and Symbolic Behavior Scales - Developmental Profile (CSBS-DP)

"The CSBS-DP was designed to measure early communication and symbolic skills in infants and young children (that is, functional communication skills of 6 month to 2 year olds). The CSBS-DP measures skills from three composites: (a) Social (emotion, eye gaze, and communication); (b) Speech (sounds and words); and (c) Symbolic (understanding and object use) and asks about developmental milestones. The data reported are the composite scores for these three categories.~The possible scores for the three composite categories are as follows:~Social Composite = 0-48; Speech Composite = 0-40; Symbolic Composite = 0-51.~A higher score indicates more advanced abilities in that area." (NCT01777542)
Timeframe: Every 5 weeks during each of the two 20-week treatment periods, and once 4 weeks after final treatment ends

,
Interventionunits on a scale (Median)
Visit 1 - First Intervention: SocialVisit 2: Social Composite ScoreVisit 3: Social Composite ScoreVisit 4: Social Composite ScoreVisit 5: Social Composite ScoreVisit 6 - Second Intervention: SocialVisit 7 - Second Intervention: SocialVisit 8 - Second Intervention: SocialVisit 9 - Second Intervention: SocialVisit 10 - Second Intervention: SocialFollow-up: Social Composite ScoreVisit 1 - First Intervention: SpeechVisit 2 - First Intervention: SpeechVisit 3 - First Intervention: SpeechVisit 4 - First Intervention: SpeechVisit 5 - First Intervention: SpeechVisit 6 - Second Intervention: SpeechVisit 7 - Second Intervention: SpeechVisit 8 - Second Intervention: SpeechVisit 9 - Second Intervention: SpeechVisit 10 - Second Intervention: SpeechFollow-up: Speech Composite ScoreVisit 1 - First Intervention: SymbolicVisit 2 - First Intervention: SymbolicVisit 3 - First Intervention: SymbolicVisit 4 - First Intervention: SymbolicVisit 5 - First Intervention: SymbolicVisit 6 - Second Intervention: SymbolicVisit 7 - Second Intervention: SymbolicVisit 8 - Second Intervention: SymbolicVisit 9 - Second Intervention: SymbolicVisit 10 - Second Intervention: SymbolicFollow-up: Symbolic Composite Score
Placebo First, Then rhIGF-119.0020.0018.0018.0020.0018.0020.0021.0021.0022.5022.504.003.005.005.506.504.004.005.005.005.006.009.5010.5010.5012.0011.5013.0010.2511.5011.5013.7514.25
rhIGF-1 First, Then Placebo22.0024.0024.0024.0023.0028.0025.0027.0029.0027.0028.007.005.008.005.008.008.507.006.505.007.256.0014.0014.5015.0014.0016.5018.5017.0017.0018.0017.0018.00

Kerr Clinical Severity Scale

"The Kerr clinical severity scale (Kerr scale) is a quantitative measure of global disease severity. The Kerr scale is a summation of individual items related to Rett syndrome phenotypic characteristics. The items are based on the severity or degree of abnormality of each characteristic on a discrete scale (0, 1, 2) with the highest level corresponding to the most severe or most abnormal presentations.~The possible range of scores is 0-48. The higher the score, the more severe the symptoms." (NCT01777542)
Timeframe: At the start and end of each 20-week treatment period

,
Interventionunits on a scale (Median)
Visit 1 - First InterventionVisit 5 - First InterventionVisit 6 - Second InterventionVisit 10 - Second Intervention
Placebo First, Then rhIGF-116.5015.0015.0014.00
rhIGF-1 First, Then Placebo18.0018.0019.0020.00

Mullen Scales of Early Learning (MSEL)

"The MSEL is a standardized developmental test for children ages 3 to 68 months consisting of five subscales: gross motor, fine motor, visual reception, expressive language, and receptive language.~The raw score is reported for each subscale domain. The potential score ranges are as follows:~Visual Reception: 33 items, score range=0-50, Fine Motor: 30 items, score range= 0-49, Receptive Language: 33 items, score range= 0-48, Expressive Language: 28 items, score range= 0-50. The gross motor subscale was not included in this population.~A higher raw score indicates more advanced abilities in that section." (NCT01777542)
Timeframe: At the start and end of each 20-week treatment period

,
Interventionunits on a scale (Median)
Visit 1- First Intervention: Visual ReceptionVisit 5- First Intervention: Visual ReceptionVisit 6- Second Intervention: Visual ReceptionVisit 10: Visual Reception Raw ScoreVisit 1- First Intervention: Fine MotorVisit 5- First Intervention: Fine MotorVisit 6- Second Intervention: Fine MotorVisit 10- Second Intervention: Fine MotorVisit 1- First Intervention: Receptive LanguageVisit 5- First Intervention: Receptive LanguageVisit 6- Second Intervention: Receptive LanguageVisit 10- Second Intervention: Receptive LanguageVisit 1- First Intervention: Expressive LanguageVisit 5- First Intervention: Expressive LanguageVisit 6- Second Intervention: Expressive LanguageVisit 10- Second Intervention: Expressive Language
Placebo First, Then rhIGF-117.0026.0023.0028.0010.009.0011.009.0020.0030.0031.0031.008.009.006.008.00
rhIGF-1 First, Then Placebo26.0039.5042.0044.007.007.0010.008.5025.5032.0038.0036.509.008.0010.008.00

Parent Targeted Visual Analog Scale (PTSVAS) - Scale 1

"The parent or caretaker identifies the three most troublesome, RTT-specific, target symptoms, such as inattention or breath-holding. This allows the problems that are of concern to parents and the family to be targeted in the trial. In this study the caregiver will choose three target symptoms at baseline and then rate changes in severity of each target symptom on a visual analog scale (VAS).~The VAS is a 10 cm line, where a target symptom is anchored on one end with the description the best it has ever been and on the other with the description the worst it has ever been. The parent was asked to marked on the line where they felt their child's symptoms currently fit best. This mark was measured as recorded as a numeric value from 0.00-10.00 cm. The higher the value, the worse the symptom." (NCT01777542)
Timeframe: Every 5 weeks during each of the two 20-week treatment periods, and once 4 weeks after final treatment ends

,
Interventionunits on a scale (Median)
Visit 1 - First InterventionVisit 2 - First InterventionVisit 3 - First InterventionVisit 4 - First InterventionVisit 5 - First InterventionVisit 6 - Second InterventionVisit 7 - Second InterventionVisit 8 - Second InterventionVisit 9 - Second InterventionVisit 10 - Second InterventionFollow-up
Placebo First, Then rhIGF-16.504.705.655.054.804.954.555.654.154.805.60
rhIGF-1 First, Then Placebo8.804.805.355.105.155.204.655.005.155.055.08

Parent Targeted Visual Analog Scale (PTSVAS) - Scale 2

"The parent or caretaker identifies the three most troublesome, RTT-specific, target symptoms, such as inattention or breath-holding. This allows the problems that are of concern to parents and the family to be targeted in the trial. In this study the caregiver will choose three target symptoms at baseline and then rate changes in severity of each target symptom on a visual analog scale (VAS).~The VAS is a 10 cm line, where a target symptom is anchored on one end with the description the best it has ever been and on the other with the description the worst it has ever been. The parent was asked to marked on the line where they felt their child's symptoms currently fit best. This mark was measured as recorded as a numeric value from 0.00-10.00 cm. The higher the value, the worse the symptom." (NCT01777542)
Timeframe: Every 5 weeks during each of the two 20-week treatment periods, and once 4 weeks after final treatment ends

,
Interventionunits on a scale (Median)
Visit 1 - First InterventionVisit 2 - First InterventionVisit 3 - First InterventionVisit 4 - First InterventionVisit 5 - First InterventionVisit 6 - Second InterventionVisit 7 - Second InterventionVisit 8 - Second InterventionVisit 9 - Second InterventionVisit 10 - Second InterventionFollow-up
Placebo First, Then rhIGF-17.754.505.855.005.005.355.505.153.804.905.15
rhIGF-1 First, Then Placebo6.355.255.955.405.457.105.855.005.134.955.20

Parent Targeted Visual Analog Scale (PTSVAS) - Scale 3

"The parent or caretaker identifies the three most troublesome, RTT-specific, target symptoms, such as inattention or breath-holding. This allows the problems that are of concern to parents and the family to be targeted in the trial. In this study the caregiver will choose three target symptoms at baseline and then rate changes in severity of each target symptom on a visual analog scale (VAS).~The VAS is a 10 cm line, where a target symptom is anchored on one end with the description the best it has ever been and on the other with the description the worst it has ever been. The parent was asked to marked on the line where they felt their child's symptoms currently fit best. This mark was measured as recorded as a numeric value from 0.00-10.00 cm. The higher the value, the worse the symptom." (NCT01777542)
Timeframe: Every 5 weeks during each of the two 20-week treatment periods, and once 4 weeks after final treatment ends

,
Interventionunits on a scale (Median)
Visit 1 - First InterventionVisit 2 - First InterventionVisit 3 - First InterventionVisit 4 - First InterventionVisit 5 - First InterventionVisit 6 - Second InterventionVisit 7 - Second InterventionVisit 8 - Second InterventionVisit 9 - Second InterventionVisit 10 - Second InterventionFollow-up
Placebo First, Then rhIGF-17.854.705.654.155.006.204.804.854.604.134.55
rhIGF-1 First, Then Placebo5.705.005.205.355.105.354.955.155.254.555.10

Parental Global Impression - Improvement (PGI-I)

"As part of each visit after the study intervention was initiated, the parent/caregiver was asked to compare the patient's overall clinical condition to the score obtained at the baseline (visit 1) visit. Based on information collected, the clinician determined if any improvement occurred on the following 7-point scale: 1=Very much improved since the initiation of treatment; 2=Much improved; 3=Minimally improved; 4=No change from baseline (the initiation of treatment); 5=Minimally worse; 6=Much worse; 7=Very much worse since the initiation of treatment.~The possible range for reported scores is 1-7." (NCT01777542)
Timeframe: Every 5 weeks during each of the two 20-week treatment periods, and once 4 weeks after final treatment ends

,
Interventionunits on a scale (Median)
Visit 2 - First InterventionVisit 3 - First InterventionVisit 4 - First InterventionVisit 5 - First InterventionVisit 6 - Second InterventionVisit 7 - Second InterventionVisit 8 - Second InterventionVisit 9 - Second InterventionVisit 10 - Second InterventionFollow-up
Placebo First, Then rhIGF-14.003.003.003.004.003.003.003.003.003.00
rhIGF-1 First, Then Placebo4.004.004.003.003.003.003.003.003.003.00

Parental Global Impression - Severity (PGI-S)

"The PGI-S is the parent version of the CGI-S. Parents/caregivers/LAR are asked to rate the severity of their child's symptoms at baseline on a 7-point scale from not at all impaired to the most impaired. The parents/caregivers/LAR will complete the PGI-S at each study visit.~The scores that correspond to each possible grouping are as follows:~1=Normal, not at all impaired; 2=Borderline impaired; 3=Mildly impaired; 4=Moderately impaired; 5=Markedly impaired; 6=Severely impaired; 7=The most impaired.~The possible range for reported scores is 1-7." (NCT01777542)
Timeframe: Every 5 weeks during each of the two 20-week treatment periods, and once 4 weeks after final treatment ends

,
Interventionunits on a scale (Median)
Visit 1 - First InterventionVisit 2 - First InterventionVisit 3 - First InterventionVisit 4 - First InterventionVisit 5 - First InterventionVisit 6 - Second InterventionVisit 7 - Second InterventionVisit 8 - Second InterventionVisit 9 - Second InterventionVisit 10 - Second InterventionFollow-up
Placebo First, Then rhIGF-14.004.004.004.004.004.004.004.004.004.004.00
rhIGF-1 First, Then Placebo6.004.004.004.004.004.004.006.006.005.004.00

Quantitative Measures of Respiration: Apnea Index

"Respiratory data was collected using non-invasive respiratory inductance plethysmography from a BioCapture® recording device. BioCapture® is a child-friendly measurement device that can record from 1 to 12 physiological signal transducers in a time-locked manner. It can be configured with the pediatric chest and abdominal plethysmography bands and the 3 lead ECG signals we plan to use for monitoring cardiac safety throughout the study. Each transducer is placed on the patient independently to provide a customized fit that yields the highest signal quality for each patient irrespective of body shape and proportion. The transducer signals captured by the BioCapture® are transmitted wirelessly to a laptop computer where all signals are displayed in real-time.~The apnea index is given as apneas/hour. Data on apneas greater than or equal to 10 seconds are displayed below. The higher the frequency of apnea, the more severe the breathing abnormality." (NCT01777542)
Timeframe: Every 10 weeks during each of the two 20-week treatment periods

,
InterventionApneas/Hour (Median)
Visit 1 - First Intervention: Apnea IndexVisit 3 - First Intervention: Apnea IndexVisit 5 - First Intervention: Apnea IndexVisit 6 - Second Intervention: Apnea IndexVisit 8 - Second Intervention: Apnea IndexVisit 10 - Second Intervention: Apnea Index
Placebo First, Then rhIGF-17.584.806.937.907.288.91
rhIGF-1 First, Then Placebo4.053.483.073.625.555.56

Rett Syndrome Behavior Questionnaire (RSBQ)

"The RSBQ is a parent-completed measure of abnormal behaviors typically observed in individuals with RTT. Each item, grouped into eight subscales, is scored on a Likert scale of 0-2, according to how well the item describes the individual's behavior. A score of 0 indicates the described item is not true, a score of 1 indicates the described item is somewhat or sometimes true, and a score of 2 indicates the described item is very true or often true.~The total sum of each subscale is reported. The higher the score, the more severe the symptoms of that subscale in the participant.~The range for each subscale is as follows:~General Mood: 0-16 Body rocking and expressionless face: 0-14 Hand behaviors: 0-12 Breathing Problems: 0-10 Repetitive Face Movements: 0-8 Night-time behaviors: 0-6 Walking Standing: 0-4~The fear/anxiety subscale was used as a primary outcome measure in this study and results can be found in that section." (NCT01777542)
Timeframe: Every 5 weeks during each of the two 20-week treatment periods, and once 4 weeks after final treatment ends

,
Interventionunits on a scale (Median)
Visit 1- First Intervention: General MoodVisit 2- First Intervention: General MoodVisit 3- First Intervention: General MoodVisit 4- First Intervention: General MoodVisit 5- First Intervention: General MoodVisit 6- Second Intervention: General MoodVisit 7- Second Intervention: General MoodVisit 8- Second Intervention: General MoodVisit 9- Second Intervention: General MoodVisit 10- Second Intervention: General MoodFollow-up: General MoodVisit 1- First Intervention: Body RockingVisit 2- First Intervention: Body RockingVisit 3- First Intervention: Body RockingVisit 4- First Intervention: Body RockingVisit 5- First Intervention: Body RockingVisit 6- Second Intervention: Body RockingVisit 7- Second Intervention: Body RockingVisit 8- Second Intervention: Body RockingVisit 9- Second Intervention: Body RockingVisit 10- Second Intervention: Body RockingFollowup: Body RockingVisit 1- First Intervention: Hand BehaviorsVisit 2- First Intervention: Hand BehaviorsVisit 3- First Intervention: Hand BehaviorsVisit 4- First Intervention: Hand BehaviorsVisit 5- First Intervention: Hand BehaviorsVisit 6- Second Intervention: Hand BehaviorsVisit 7- Second Intervention: Hand BehaviorsVisit 8- Second Intervention: Hand BehaviorsVisit 9- Second Intervention: Hand BehaviorsVisit 10- Second Intervention: Hand BehaviorsFollow-up: Hand BehaviorsVisit 1- First Intervention: Breathing ProblemsVisit 2- First Intervention: Breathing ProblemsVisit 3- First Intervention: Breathing ProblemsVisit 4- First Intervention: Breathing ProblemsVisit 5- First Intervention: Breathing ProblemsVisit 6- Second Intervention: Breathing ProblemsVisit 7- Second Intervention: Breathing ProblemsVisit 8- Second Intervention: Breathing ProblemsVisit 9- Second Intervention: Breathing ProblemsVisit 10- Second Intervention: Breathing ProblemsFollow-up: Breathing ProblemsVisit 1- First Intervention: Repetitive Face MovemVisit 2- First Intervention: Repetitive Face MovemVisit 3- First Intervention: Repetitive Face MovemVisit 4- First Intervention: Repetitive Face MovemVisit 5- First Intervention: Repetitive Face MovemVisit 6- Second Intervention: Repetitive Face MovVisit 7- Second Intervention: Repetitive Face MovVisit 8- Second Intervention: Repetitive Face MovVisit 9- Second Intervention: Repetitive Face MovVisit 10- Second Intervention: Repetitive Face MovFollow-up: Repetitive Face MovementsVisit 1- First Intervention: Night time BehaviorsVisit 2- First Intervention: Night time BehaviorsVisit 3- First Intervention: Night time BehaviorsVisit 4- First Intervention: Night time BehaviorsVisit 5- First Intervention: Night time BehaviorsVisit 6- Second Intervention: Night time BehaviorVisit 7- Second Intervention: Night time BehaviorVisit 8- Second Intervention: Night time BehaviorVisit 9- Second Intervention: Night time BehaviorVisit 10- Second Intervention: Night time BehaviorFollow-up: Night time BehaviorsVisit 1- First Intervention: Walking/StandingVisit 2- First Intervention: Walking/StandingVisit 3- First Intervention: Walking/StandingVisit 4- First Intervention: Walking/StandingVisit 5- First Intervention: Walking/StandingVisit 6- Second Intervention: Walking/StandingVisit 7- Second Intervention: Walking/StandingVisit 8- Second Intervention: Walking/StandingVisit 9- Second Intervention: Walking/StandingVisit 10- Second Intervention: Walking/StandingFollow-up: Walking/Standing
Placebo First, Then rhIGF-17.005.006.005.005.004.005.505.006.004.005.506.005.005.006.005.004.005.005.004.005.004.508.009.008.008.008.009.008.008.008.007.007.506.004.005.005.005.006.004.506.005.006.005.002.002.003.002.003.003.003.003.003.003.002.000.000.000.000.000.000.000.001.000.000.000.002.002.002.002.002.002.002.002.003.001.502.00
rhIGF-1 First, Then Placebo4.003.002.002.003.004.002.002.001.002.502.004.004.003.004.004.004.003.004.003.004.004.008.008.008.009.009.008.009.009.007.009.008.504.004.004.005.004.004.003.003.003.004.003.002.002.003.002.002.003.002.002.002.001.502.001.001.000.000.001.001.000.000.000.000.000.002.002.002.002.002.002.002.002.002.002.002.00

Rett Syndrome Behavior Questionnaire (RSBQ) - Fear/Anxiety Subscale

"The RSBQ is an informant/parent-completed measure of abnormal behaviors typically observed in individuals with RTT, which is completed by a parent/caregiver/LAR. Each item, grouped into eight domains/factors: General mood, Breathing problems, Body rocking and expressionless face, Hand behaviors, Repetitive face movements, Night-time behaviors, Fear/anxiety and Walking/standing), is scored on a Likert scale of 0-2, according to how well the item describes the individual's behavior. A score of 0 indicates the described item is not true, a score of 1 indicates the described item is somewhat or sometimes true, and a score of 2 indicates the described item is very true or often true.~The total sum of items in each subscale is reported.~For the fear/anxiety subscale, the sum total could be between 0-8. The higher the sum total score, the greater the frequency of fear/anxiety behaviors." (NCT01777542)
Timeframe: Every 5 weeks during each of the two 20-week treatment periods, and once 4 weeks after final treatment ends

,
Interventionunits on a scale (Median)
Visit 1 - First InterventionVisit 2 - First InterventionVisit 3 - First InterventionVisit 4 - First InterventionVisit 5 - First InterventionVisit 6 - Second InterventionVisit 7 - Second InterventionVisit 8 - Second InterventionVisit 9 - Second InterventionVisit 10 - Second InterventionFollow-up
Placebo First, Then rhIGF-14.005.004.004.003.004.004.003.003.004.003.50
rhIGF-1 First, Then Placebo5.003.003.003.003.004.003.004.003.003.003.50

Vineland Adaptive Behavior Scales, Second Edition (VABS-II)

"The VABS-II is a survey designed to assess personal and social functioning. Within each domain (Communication, Daily Living Skills, Socialization, and Motor Skills), items can given a score of 2 if the participant successfully performs the activity usually; a 1 if the participant successfully performs the activity sometimes, or needs reminders; a 0 if the participant never performs the activity, and a DK if the parent/caregiver is unsure of the participant's ability for an item.~The raw scores in each sub-domain are reported and the ranges for these are as follows: [Communication Domain], Receptive Language=0-40, Expressive Language=0-108, Written Language=0-50; [Daily Living Skills Domain], Personal=0-82, Domestic=0-48, Community=0-88; [Socialization Domain], Interpersonal Relationships=0-76, Play and Leisure Time=0-62, Coping Skills=0-60; [Motor Skills Domain]: Gross Motor Skills=0-80, Fine Motor Skills=0-72.~A higher score indicates more advanced abilities." (NCT01777542)
Timeframe: At the start and end of each 20-week treatment period

,
Interventionunits on a scale (Median)
Visit 1 - First Intervention: ReceptiveVisit 5 - First Intervention: ReceptiveVisit 6 - Second Intervention: Receptive LanguageVisit 10 - Second Intervention: Receptive LanguageVisit 1 - First Intervention: ExpressiveVisit 5 - First Intervention: ExpressiveVisit 6 - Second Intervention: Expressive Lang.Visit 10 - Second Intervention: Expressive Lang.Visit 1 - First Intervention: WrittenVisit 5 - First Intervention: WrittenVisit 6: - Second Intervention Written LanguageVisit 10 - Second Intervention: Written LanguageVisit 1 - First Intervention: PersonalVisit 5 - First Intervention: PersonalVisit 6 - Second Intervention: PersonalVisit 10 - Second Intervention: PersonalVisit 1 - First Intervention: DomesticVisit 5 - First Intervention: DomesticVisit 6 - Second Intervention: DomesticVisit 10 - Second Intervention: DomesticVisit 1 - First Intervention: CommunityVisit 5 - First Intervention: CommunityVisit 6 - Second Intervention: CommunityVisit 10 - Second Intervention: CommunityVisit 1 - First Intervention: Interpersonal Rel.Visit 5 - First Intervention: Interpersonal Rel.Visit 6 - Second Intervention: Interpersonal Rel.Visit 10 - Second Intervention: Interpersonal Rel.Visit 1 - First Intervention: Play and LeisureVisit 5 - First Intervention: Play and LeisureVisit 6 - Second Intervention: Play and LeisureVisit 10 - Second Intervention: Play and LeisureVisit 1 - First Intervention: Coping SkillsVisit 5 - First Intervention: Coping SkillsVisit 6 - Second Intervention: Coping SkillsVisit 10 - Second Intervention: Coping SkillsVisit 1 - First Intervention: Gross MotorVisit 5 - First Intervention: Gross MotorVisit 6 - Second Intervention: Gross MotorVisit 10 - Second Intervention: Gross MotorVisit 1 - First Intervention: Fine MotorVisit 5 - First Intervention: Fine MotorVisit 6 - Second Intervention: Fine MotorVisit 10 - Second Intervention: Fine Motor
Placebo First, Then rhIGF-113.0015.0018.0020.0016.0017.0018.0020.000.000.004.006.009.0010.009.0010.000.000.000.000.000.001.001.002.0018.0018.0019.0020.008.0011.0012.0011.003.002.003.004.0031.0034.0027.0027.006.006.007.005.00
rhIGF-1 First, Then Placebo18.0021.0022.0024.5018.0022.0025.0024.004.005.007.007.008.009.008.509.500.000.000.000.003.003.005.005.0021.0022.0021.0022.5013.0012.0013.0012.503.004.006.004.5010.0010.0011.5010.502.003.004.004.00

Reviews

7 reviews available for caffeine and ADDH

ArticleYear
Effects of Caffeine Consumption on Attention Deficit Hyperactivity Disorder (ADHD) Treatment: A Systematic Review of Animal Studies.
    Nutrients, 2022, Feb-10, Volume: 14, Issue:4

    Topics: Animals; Attention Deficit Disorder with Hyperactivity; Caffeine; Disease Models, Animal; Dopamine;

2022
Prenatal smoking, alcohol and caffeine exposure and offspring externalizing disorders: a systematic review and meta-analysis.
    Addiction (Abingdon, England), 2022, Volume: 117, Issue:10

    Topics: Attention Deficit Disorder with Hyperactivity; Caffeine; Conduct Disorder; Ethanol; Female; Humans;

2022
Ostracising caffeine from the pharmacological arsenal for attention-deficit hyperactivity disorder--was this a correct decision? A literature review.
    Journal of psychopharmacology (Oxford, England), 2014, Volume: 28, Issue:9

    Topics: Attention Deficit Disorder with Hyperactivity; Brain; Caffeine; Cognition Disorders; Humans; Puriner

2014
[Caffeine consumption during pregnancy and attention deficit hyperactivity disorder (ADHD): a systematic literature review].
    Cadernos de saude publica, 2015, Volume: 31, Issue:4

    Topics: Attention Deficit Disorder with Hyperactivity; Brazil; Caffeine; Central Nervous System Stimulants;

2015
Maternal lifestyle factors in pregnancy risk of attention deficit hyperactivity disorder and associated behaviors: review of the current evidence.
    The American journal of psychiatry, 2003, Volume: 160, Issue:6

    Topics: Adolescent; Adult; Alcohol Drinking; Attention Deficit Disorder with Hyperactivity; Caffeine; Child;

2003
Hyperactivity: is candy causal?
    Critical reviews in food science and nutrition, 1996, Volume: 36, Issue:1-2

    Topics: Attention Deficit Disorder with Hyperactivity; Cacao; Caffeine; Candy; Child; Child, Preschool; Fema

1996
Physiologic and psychotropic effects of caffeine on man. A review.
    Journal of the American Dietetic Association, 1977, Volume: 71, Issue:3

    Topics: Adolescent; Adult; Age Factors; Aged; Attention Deficit Disorder with Hyperactivity; Cacao; Caffeine

1977

Trials

8 trials available for caffeine and ADDH

ArticleYear
Effects of L-theanine-caffeine combination on sustained attention and inhibitory control among children with ADHD: a proof-of-concept neuroimaging RCT.
    Scientific reports, 2020, 08-04, Volume: 10, Issue:1

    Topics: Adolescent; Attention; Attention Deficit Disorder with Hyperactivity; Brain; Caffeine; Child; Cognit

2020
Caffeine effects on resting-state electrodermal levels in AD/HD suggest an anomalous arousal mechanism.
    Biological psychology, 2012, Volume: 89, Issue:3

    Topics: Adolescent; Analysis of Variance; Attention Deficit Disorder with Hyperactivity; Caffeine; Case-Cont

2012
Responses to methylphenidate and varied doses of caffeine in children with attention deficit disorder.
    Canadian journal of psychiatry. Revue canadienne de psychiatrie, 1981, Volume: 26, Issue:6

    Topics: Attention Deficit Disorder with Hyperactivity; Caffeine; Child; Clinical Trials as Topic; Dose-Respo

1981
Methylphenidate vs dextroamphetamine vs caffeine in minimal brain dysfunction: controlled comparison by placebo washout design with Bayes' analysis.
    Archives of general psychiatry, 1978, Volume: 35, Issue:4

    Topics: Attention Deficit Disorder with Hyperactivity; Caffeine; Child; Child, Preschool; Clinical Trials as

1978
Individual responses to methylphenidate and caffeine in children with minimal brain dysfunction.
    Canadian Medical Association journal, 1975, Oct-18, Volume: 113, Issue:8

    Topics: Attention Deficit Disorder with Hyperactivity; Caffeine; Child; Citrates; Clinical Trials as Topic;

1975
Methylphenidate and caffeine in the treatment of children with minimal brain dysfunction.
    The American journal of psychiatry, 1975, Volume: 132, Issue:7

    Topics: Administration, Oral; Attention Deficit Disorder with Hyperactivity; Caffeine; Child; Clinical Trial

1975
Caffeine versus methylphenidate and d-amphetamine in minimal brain dysfunction: a double-blind comparison.
    The American journal of psychiatry, 1975, Volume: 132, Issue:8

    Topics: Amphetamine; Attention Deficit Disorder with Hyperactivity; Caffeine; Child; Child, Preschool; Clini

1975
Caffeine in the treatment of children with minimal brain dysfunction or hyperkinetic syndrome.
    Psychosomatics, 1975, Volume: 16, Issue:1

    Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Caffeine; Child; Child, Preschool; Clinic

1975

Other Studies

30 other studies available for caffeine and ADDH

ArticleYear
Prenatal smoking, alcohol and caffeine exposure and maternal-reported attention deficit hyperactivity disorder symptoms in childhood: triangulation of evidence using negative control and polygenic risk score analyses.
    Addiction (Abingdon, England), 2022, Volume: 117, Issue:5

    Topics: Attention Deficit Disorder with Hyperactivity; Caffeine; Cohort Studies; Female; Humans; Longitudina

2022
Caffeine-related genes influence anxiety disorders in children and adults with ADHD.
    Journal of psychiatric research, 2022, Volume: 145

    Topics: Adult; Anxiety; Anxiety Disorders; Attention Deficit Disorder with Hyperactivity; Caffeine; Central

2022
Attention-deficit/hyperactivity disorder, headache and caffeine.
    Psychological medicine, 2022, Volume: 52, Issue:1

    Topics: Attention Deficit Disorder with Hyperactivity; Caffeine; Central Nervous System Stimulants; Headache

2022
Twin study of caffeine use, ADHD, and disrupted sleep in ABCD youth.
    Health psychology : official journal of the Division of Health Psychology, American Psychological Association, 2023, Volume: 42, Issue:12

    Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Caffeine; Child; Female; Humans; Male

2023
Twin study of caffeine use, ADHD, and disrupted sleep in ABCD youth.
    Health psychology : official journal of the Division of Health Psychology, American Psychological Association, 2023, Volume: 42, Issue:12

    Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Caffeine; Child; Female; Humans; Male

2023
Twin study of caffeine use, ADHD, and disrupted sleep in ABCD youth.
    Health psychology : official journal of the Division of Health Psychology, American Psychological Association, 2023, Volume: 42, Issue:12

    Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Caffeine; Child; Female; Humans; Male

2023
Twin study of caffeine use, ADHD, and disrupted sleep in ABCD youth.
    Health psychology : official journal of the Division of Health Psychology, American Psychological Association, 2023, Volume: 42, Issue:12

    Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Caffeine; Child; Female; Humans; Male

2023
LSGP-USFNet: Automated Attention Deficit Hyperactivity Disorder Detection Using Locations of Sophie Germain's Primes on Ulam's Spiral-Based Features with Electroencephalogram Signals.
    Sensors (Basel, Switzerland), 2023, Aug-08, Volume: 23, Issue:16

    Topics: Algorithms; Anxiety; Anxiety Disorders; Attention Deficit Disorder with Hyperactivity; Caffeine; Chi

2023
Caffeine and adenosine A
    Neuropharmacology, 2020, Volume: 166

    Topics: Adenosine A1 Receptor Antagonists; Adenosine A2 Receptor Agonists; Animals; Attention Deficit Disord

2020
Caffeine Use and Associations With Sleep in Adolescents With and Without ADHD.
    Journal of pediatric psychology, 2020, 07-01, Volume: 45, Issue:6

    Topics: Actigraphy; Adolescent; Attention Deficit Disorder with Hyperactivity; Caffeine; Child; Humans; Slee

2020
Caffeine Consumption plus Physical Exercise Improves Behavioral Impairments and Stimulates Neuroplasticity in Spontaneously Hypertensive Rats (SHR): an Animal Model of Attention Deficit Hyperactivity Disorder.
    Molecular neurobiology, 2020, Volume: 57, Issue:9

    Topics: Aging; Animals; Attention Deficit Disorder with Hyperactivity; Behavior, Animal; Brain; Brain-Derive

2020
Differential Behavioral and Biochemical Responses to Caffeine in Male and Female Rats from a Validated Model of Attention Deficit and Hyperactivity Disorder.
    Molecular neurobiology, 2018, Volume: 55, Issue:11

    Topics: Animals; Attention Deficit Disorder with Hyperactivity; Behavior, Animal; Brain-Derived Neurotrophic

2018
Caffeine and cannabinoid receptors modulate impulsive behavior in an animal model of attentional deficit and hyperactivity disorder.
    The European journal of neuroscience, 2019, Volume: 49, Issue:12

    Topics: Animals; Attention Deficit Disorder with Hyperactivity; Benzoxazines; Caffeine; Cannabinoid Receptor

2019
The billion dollar business of being smart.
    BMJ (Clinical research ed.), 2015, Sep-14, Volume: 351

    Topics: Amphetamine; Attention Deficit Disorder with Hyperactivity; Caffeine; Central Nervous System Stimula

2015
Caffeine consumption during pregnancy and ADHD at the age of 11 years: a birth cohort study.
    BMJ open, 2016, 12-05, Volume: 6, Issue:12

    Topics: Adult; Attention Deficit Disorder with Hyperactivity; Brazil; Caffeine; Central Nervous System Stimu

2016
Coffee consumption during pregnancy and the risk of hyperkinetic disorder and ADHD: a prospective cohort study.
    Acta paediatrica (Oslo, Norway : 1992), 2009, Volume: 98, Issue:1

    Topics: Adolescent; Adult; Attention Deficit Disorder with Hyperactivity; Caffeine; Central Nervous System S

2009
Adenosine receptor antagonists improve short-term object-recognition ability of spontaneously hypertensive rats: a rodent model of attention-deficit hyperactivity disorder.
    Behavioural pharmacology, 2009, Volume: 20, Issue:2

    Topics: Adenosine A1 Receptor Antagonists; Adenosine A2 Receptor Antagonists; Animals; Attention Deficit Dis

2009
Intrauterine exposure to caffeine and inattention/overactivity in children.
    Acta paediatrica (Oslo, Norway : 1992), 2010, Volume: 99, Issue:6

    Topics: Adolescent; Adult; Analysis of Variance; Attention Deficit Disorder with Hyperactivity; Caffeine; Fe

2010
Chronic caffeine treatment during prepubertal period confers long-term cognitive benefits in adult spontaneously hypertensive rats (SHR), an animal model of attention deficit hyperactivity disorder (ADHD).
    Behavioural brain research, 2010, Dec-20, Volume: 215, Issue:1

    Topics: Analysis of Variance; Animals; Attention Deficit Disorder with Hyperactivity; Blood Pressure; Caffei

2010
Tea consumption maybe an effective active treatment for adult attention deficit hyperactivity disorder (ADHD).
    Medical hypotheses, 2011, Volume: 76, Issue:4

    Topics: Adult; Attention Deficit Disorder with Hyperactivity; Caffeine; Central Nervous System Stimulants; H

2011
Caffeine improves attention deficit in neonatal 6-OHDA lesioned rats, an animal model of attention deficit hyperactivity disorder (ADHD).
    Neuroscience letters, 2011, Apr-20, Volume: 494, Issue:1

    Topics: Animals; Attention; Attention Deficit Disorder with Hyperactivity; Caffeine; Central Nervous System

2011
Caffeine regulates frontocorticostriatal dopamine transporter density and improves attention and cognitive deficits in an animal model of attention deficit hyperactivity disorder.
    European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, 2013, Volume: 23, Issue:4

    Topics: Animals; Attention; Attention Deficit Disorder with Hyperactivity; Caffeine; Cognition Disorders; Co

2013
Caffeine intake during pregnancy and risk of problem behavior in 5- to 6-year-old children.
    Pediatrics, 2012, Volume: 130, Issue:2

    Topics: Affective Symptoms; Attention Deficit Disorder with Hyperactivity; Caffeine; Child; Child Behavior D

2012
Social isolation induces deficit of latent learning performance in mice: a putative animal model of attention deficit/hyperactivity disorder.
    Behavioural brain research, 2013, Feb-01, Volume: 238

    Topics: Aggression; Animals; Attention; Attention Deficit Disorder with Hyperactivity; Caffeine; Central Ner

2013
Acute onset of bilateral myoclonus in a 16-year-old female.
    Journal of the Mississippi State Medical Association, 2004, Volume: 45, Issue:6

    Topics: Acetaminophen; Acute Disease; Adolescent; Aspirin; Attention Deficit Disorder with Hyperactivity; Ca

2004
Heterogeneity in phenotypes based on smoking status in the Great Lakes Smoker Sibling Registry.
    Addictive behaviors, 2004, Volume: 29, Issue:9

    Topics: Adult; Alcohol Drinking; Alcohol-Related Disorders; Attention Deficit Disorder with Hyperactivity; C

2004
[Caffeine, cannabis and cocaine: from automedication to 'automutilation' in adults with ADHD].
    Nederlands tijdschrift voor geneeskunde, 2004, Dec-25, Volume: 148, Issue:52

    Topics: Adult; Attention Deficit Disorder with Hyperactivity; Caffeine; Central Nervous System Stimulants; C

2004
Caffeine improves spatial learning deficits in an animal model of attention deficit hyperactivity disorder (ADHD) -- the spontaneously hypertensive rat (SHR).
    The international journal of neuropsychopharmacology, 2005, Volume: 8, Issue:4

    Topics: Animals; Attention Deficit Disorder with Hyperactivity; Blood Pressure; Caffeine; Central Nervous Sy

2005
Caffeine use by children: the quest for enhancement.
    Substance use & misuse, 2007, Volume: 42, Issue:8

    Topics: Achievement; Adolescent; Adult; Attention Deficit Disorder with Hyperactivity; Biomedical Enhancemen

2007
Hyperactivity and inattention--a successful response to table coffee.
    Nigerian journal of clinical practice, 2007, Volume: 10, Issue:2

    Topics: Attention Deficit Disorder with Hyperactivity; Caffeine; Central Nervous System Stimulants; Child, P

2007
Caffeine consumption, sleep, and affect in the natural environments of depressed youth and healthy controls.
    Journal of pediatric psychology, 2008, Volume: 33, Issue:4

    Topics: Adolescent; Affect; Anxiety Disorders; Attention Deficit Disorder with Hyperactivity; Beverages; Caf

2008
Diet and hyperactivity.
    Nutrition reviews, 1986, Volume: 44 Suppl

    Topics: Alcohol Drinking; Arousal; Attention Deficit Disorder with Hyperactivity; Brain; Caffeine; Child; Fe

1986
Will population decreases in caffeine consumption unveil attention deficit disorders in adults?
    Medical hypotheses, 1985, Volume: 18, Issue:2

    Topics: Adult; Attention Deficit Disorder with Hyperactivity; Behavior; Caffeine; Child; Coffee; Humans

1985